Lipocine (LPCN) Other Non Operating Income (2018 - 2024)
Lipocine's (LPCN) quarterly Other Non Operating Income came in at $466758.0 in Q4 2024, up 99.09% YoY from $234442.0 in Q1 2024, and up 238.03% on a QoQ basis from $138081.0 in Q3 2024.
Lipocine (LPCN) Other Non Operating Income (2018 - 2024) Analysis & Trends
Lipocine (LPCN) has 7 years of Other Non Operating Income data on file, last reported at $466758.0 in Q4 2024.
- Quarterly Other Non Operating Income rose 99.09% year-over-year to $466758.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $480337.0 (up 10.46% YoY) and the FY2024 annual result came in at $480338.0, up 10.46% from the prior year.
- Other Non Operating Income climbed to $466758.0 in Q4 2024, from $138081.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $583445.0 in Q2 2022 to a low of -$3.8 million in Q2 2021.
- A 5-year average of -$258033.4 and a median of $54535.0 in 2022 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2020 — Other Non Operating Income plunged 2584.1% — and 2023, when it jumped 584.64%.
- Tracing LPCN's Other Non Operating Income over 5 years: stood at $290398.0 in 2020, then tumbled by 155.07% to -$159926.0 in 2021, then surged by 121.41% to $34243.0 in 2022, then jumped by 584.64% to $234442.0 in 2023, then surged by 99.09% to $466758.0 in 2024.
- The last three Other Non Operating Income figures came in at $466758.0 (Q4 2024), $138081.0 (Q3 2024), and -$84430.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 466,758.00 |
| Sep 30, 2024 | 138,081.00 |
| Jun 30, 2024 | -84,430.00 |
| Mar 31, 2024 | -40,072.00 |
| Dec 31, 2023 | 234,442.00 |
| Sep 30, 2023 | 74,827.00 |
| Jun 30, 2023 | 27,455.00 |
| Mar 31, 2023 | 98,134.00 |
| Dec 31, 2022 | 34,243.00 |
| Sep 30, 2022 | 326,240.00 |
| Jun 30, 2022 | 583,445.00 |
| Mar 31, 2022 | -377,988.00 |
| Dec 31, 2021 | -159,926.00 |
| Sep 30, 2021 | 479,951.00 |
| Jun 30, 2021 | -3.82 Mn |
| Mar 31, 2021 | -253,389.00 |
| Dec 31, 2020 | 290,398.00 |
| Sep 30, 2020 | 140,477.00 |
| Jun 30, 2020 | -2.15 Mn |
| Mar 31, 2020 | -1.17 Mn |